Skip to main content
. 2021 Feb 10;11(2):263. doi: 10.3390/biom11020263

Figure 1.

Figure 1

Therapeutic efficacy following administration of 100 MBq of [177Lu]Lu-PSMA-617 with vehicle or with recombinant α1-microglobulin (rA1M) (5 mg/kg). (A) [177Lu]Lu-PSMA-617 tumor uptake 24 h post injection, quantified from single photon emission computed tomography (SPECT) images, in mice given rA1M or vehicle (Data presented as mean ± SEM). The uptake was 5.2 ± 2.3 percent injected activity per gram (% IA/g) (n = 8) for mice treated with [177Lu]Lu-PSMA-617 and rA1M compared to 3.6 ± 1.8% IA/g (n = 8) for mice treated with [177Lu]Lu-PSMA-617 and vehicle, the difference was not significant (n.s.). (B) Tumor uptake as a function of tumor size. (C) Treatment response of the LNCaP xenografts over time, presented as the relative tumor size compared to tumor volume at start (mean ± SD). (D) White blood cells (WBC), red blood cells (RBC) and platelet (PLT) counts for mice treated with [177Lu]Lu-PSMA-617 given rA1M or vehicle (mean ± SD).